Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19

Condition:   SARS-CoV-2 Intervention:   Sponsor:   ModernaTX, Inc. Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials